Who are Low-dose PRP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Autologous platelets rich plasma, Leukocyte rich platelet rich plasma.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-prp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Low-dose PRP — Competitive Intelligence Brief

Low-dose PRP (Low-dose PRP) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Autologous cell therapy / Regenerative medicine product. Area: Orthopedics / Regenerative Medicine.

marketed Autologous cell therapy / Regenerative medicine product Orthopedics / Regenerative Medicine Biologic Live · refreshed every 30 min

Target snapshot

Low-dose PRP (Low-dose PRP) — Hospital for Special Surgery, New York. Low-dose PRP (platelet-rich plasma) delivers concentrated platelets and growth factors to damaged tissues to promote healing and reduce inflammation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Low-dose PRP TARGET	Low-dose PRP	Hospital for Special Surgery, New York	marketed	Autologous cell therapy / Regenerative medicine product
Autologous platelets rich plasma	Autologous platelets rich plasma	Mostafa Hassanein, Msc	marketed	Autologous cell therapy / Regenerative medicine product
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Autologous cell therapy / Regenerative medicine product class)

Hospital for Special Surgery, New York · 1 drug in this class
Mostafa Hassanein, Msc · 1 drug in this class
University Hospitals Cleveland Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low-dose PRP — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-prp. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab